Skip to content

The ED Watch is reader-supported and may earn commissions. Advertising disclosure · Not medical advice

BlueChew · Individual product review

BlueChew VMAX review

BlueChew VMAX: a two-PDE5 prescription with additional rhythm-history considerations, with formulation, cost, evidence and availability examined to monitor the offer, the evidence and the plan after prescribing.

The ED Watch editorial desk · Published October 7, 2026 · Updated October 7, 2026
AI-assisted public-document research · Not medically reviewed · No firsthand product testing

We may earn a commission through commercial links. This review does not award a clinical rating. Read the disclosure.

BlueChew VMAX deserves a review separate from the BlueChew service because it identifies vardenafil 14 mg plus tadalafil 18 mg. The relevant questions concern this preparation's evidence, complete cost and follow-up, not a single score for everything the company sells. This product watch records what the current public material can establish and what still needs confirmation.

The exact product

The feature to watch is a two-PDE5 prescription with additional rhythm-history considerations. Match the full ingredient list and dosage form to the prescription actually offered. A company may market conventional tablets, daily products and compounds simultaneously. A service review can describe access or billing while leaving the differences between those medicines unresolved. The identity record below is therefore the starting point for interpreting every price or clinical claim on this page.

The exact product: product details
ProviderBlueChew
Listed active ingredientsVardenafil 14 mg + tadalafil 18 mg
Dosage formCompounded sublingual tablet
Regulatory distinctionCompounded preparation; the finished product is not FDA-approved.
Source basisBlueChew: product-specific approximate costs · BlueChew: product access and legacy-plan notice · BlueChew: VMAX product information

Price, supply and payment

The public cost entry is Product page: from $5.63 each; plan unverified. Watch the payment interval and supplied quantity as closely as the headline. An introductory amount, an approximate article example and a complete renewal quote have different evidentiary value. Do not combine a unit figure from one plan with a monthly banner from another. Save the selected order terms so that a later refill or treatment change can be checked against them.

Price, supply and payment: product details
Unit headlineFrom $5.63 each
Availability noticeExisting customers already enrolled; confirm with the account
Format wordingDirect page and articles use chewable and sublingual descriptions
Evidence boundarySildenafil/tadalafil findings cannot be transferred to this different pair

What the research can support

The research relevant to the offer concerns component information; no randomized finished-VMAX comparison verified. It leaves current account eligibility, formulation directions and complete quote unverified. That boundary prevents ingredient studies or provider satisfaction surveys from turning into finished-product efficacy scores. Ask whether a quoted timing or performance result measured the exact preparation and a clinically relevant outcome. A useful review can recognize an evidence gap without asserting that an unstudied product must be ineffective.

What the research can support: product details
Evidence boundarycomponent information; no randomized finished-VMAX comparison verified
Not established herecurrent account eligibility, formulation directions and complete quote
Clinical and regulatory referencesMedlinePlus: Vardenafil · DailyMed: Tadalafil prescribing information, including section 5.11 · FDA: Compounding and the FDA — questions and answers · MedlinePlus: Sildenafil · MedlinePlus: Tadalafil

Safety questions for the prescriber

Monitoring starts with accurate prescribing information. Disclose nitrates or recreational nitrites, riociguat, other ED medicines, blood-pressure treatment and relevant heart, kidney, liver or eye history. Do not add BlueChew VMAX to an existing regimen without individualized instructions. The ingredient-specific consideration below should be addressed before a treatment change, not discovered only after an automatic refill has created overlapping supplies.

Safety questions for the prescriber: product details
Multiple PDE5 inhibitorsStandard tadalafil labeling advises against combining PDE5 inhibitors; individualized rationale and monitoring are needed.
VardenafilQT/rhythm history and interacting medicines need explicit review.

Availability and the actual prescription

The current availability finding is Provider notice: existing enrolled customers only; confirm account eligibility. Treat this as a dated documentary observation. Account eligibility and product catalogs can change, while public safety pages may remain accessible. Confirm the actual offered medicine, quantity and pharmacy instructions when enrolling or switching. A reachable page is not evidence that a new prescription or new-customer plan has been approved.

Refills, changes and cancellation

The next step to watch is the response review. Record whether the original concern improved, what unwanted effects occurred and whether the instructions were followed. Ask the clinician “What makes vardenafil preferable in this combination given my medicines and rhythm history?” Then confirm any treatment change in the next shipment and billing record. Administrative cancellation and clinical stopping instructions are separate states; one should not be inferred from the other.

Refills, changes and cancellation: product details
Hold choicesA one-order skip differs from an indefinite stop-until-return setting.
Cancellation noticeAt least 24 hours before renewal in the published policy.
Clinical plan changesAccount FAQ requests 48 hours; changes do not affect an order already processing.
ReturnsPrescription returns are not accepted.
Policy sourcesBlueChew: account and subscription questions · BlueChew: returns and refunds policy

Compare named products

Use the linked alternatives to examine a concrete change in ingredient, form, schedule or commitment. They are not ordered by clinical superiority. A provider's customer-service features cannot establish the efficacy of a medicine, and a medicine's established evidence cannot verify one provider's delivery or prescribing quality. Keep those judgments separate when deciding what to investigate next.

Questions to keep with the offer

This watch is based on public-source research, with no medical reviewer and no firsthand trial of BlueChew VMAX. We have not tested the checkout, medicine, support response or refund process. The cited records explain the advertised offer and evidence limits. Personal suitability, a complete accepted quote and a workable monitoring plan still require the responsible clinical and service teams.

Questions to keep with the offer: product details
Ask about this formulaWhat makes vardenafil preferable in this combination given my medicines and rhythm history?
Ask about the paymentWhat are the exact quantity, total due now, renewal amount and notice deadline?
Ask about a changeWho confirms the medical instructions, pharmacy order and next account charge?

When to get urgent help

An erection lasting more than four hours or chest pain requires emergency care. Tell the treating clinician what was taken and when.

Sudden hearing or vision loss needs prompt medical attention. Do not wait for an ordinary account-support reply.

Original sources

Provider pages document an advertised offer. Regulatory records and studies address different questions; an ingredient study does not establish a finished compounded product's outcomes.

  1. BlueChew: product-specific approximate costsProvider price examples; approximate and not necessarily consistent with other offer pages · Checked 2026-10-07
  2. BlueChew: product access and legacy-plan noticeProvider article; restricts certain products to existing enrolled customers; confirm account eligibility · Checked 2026-10-07
  3. BlueChew: VMAX product informationProvider product page; vardenafil and tadalafil strengths · Checked 2026-10-07
  4. MedlinePlus: VardenafilGovernment patient drug information; standard products, not compounded equivalents · Checked 2026-10-07
  5. BlueChew: account and subscription questionsProvider policy; plan changes, one-order skips, and indefinite holds · Checked 2026-10-07
  6. BlueChew: shipping and delivery questionsProvider policy; destination availability, shipping, and renewal terms · Checked 2026-10-07
  7. BlueChew: returns and refunds policyProvider policy; prescription returns and 24-hour cancellation notice · Checked 2026-10-07
  8. DailyMed: Tadalafil prescribing information, including section 5.11Prescribing label; not evidence for the 4Play combination · Checked 2026-10-07
  9. FDA: Compounding and the FDA — questions and answersGovernment guidance on compounded medications · Checked 2026-10-07
  10. MedlinePlus: SildenafilDrug information; standard sildenafil products · Checked 2026-10-07
  11. MedlinePlus: TadalafilDrug information; standard tadalafil products · Checked 2026-10-07

Continue with a named product

Browse all individual product reviews →